| Trial ID: | L5820 |
| Source ID: | NCT02287285
|
| Associated Drug: |
Exendin9
|
| Title: |
Determinants of Diabetes Remission After Gastric Bypass Surgery
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Exendin9
|
| Outcome Measures: |
Primary: Beta Cell Sensitivity (BCS), Oral glucose tolerance test (OGTT) will be used to calculate BCS Graded glucose infusion with arginine (GGI) will be used to calculate BCS, at 2 years post GBP surgery | Secondary: Insulin Secretion Rate (ISR) after OGTT, An oral glucose tolerance test (OGTT) will be used to estimate ISR in subjects before and up to 2 years after GBP, 2 years post GBP surgery|Insulin Secretion Rate (ISR) after GGI, A graded glucose infusion with arginine (GGI) will be used to estimate ISR in subjects before and up to 2 years after GBP, 2 years post GBP surgery|Maximal Beta Cell Function, The effect of a graded glucose infusion with arginine (GGI) on insulin secretion rate (ISR) will be measured in subjects before and up to 2 years after GBP, 2 years post GBP surgery
|
| Sponsor/Collaborators: |
Sponsor: Blandine Laferrere | Collaborators: National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
25
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-10
|
| Completion Date: |
2019-07
|
| Results First Posted: |
|
| Last Update Posted: |
2020-04-24
|
| Locations: |
New York Obesity Research Center, Columbia University, New York, New York, 10032, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02287285
|
